Skip to Main Content

As it pursues Mylan Pharmaceuticals for $100 million in taxes, the Internal Revenue Service is accusing the drug maker of bad faith in complying with ongoing requests to cough up documents needed for a looming trial.

In court documents filed last month, the IRS alleges that Mylan has “repeated false assurances and [offered] incomplete responses” to its efforts to obtain materials over the past two years. And the failure to produce the documents is “inexcusable,” the IRS wrote in a motion asking the US Tax Court to force the company to turn over emails, correspondence, and other paperwork (see here, here and here).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!